Your session is about to expire
← Back to Search
CRX100 for Solid Cancers
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective. The drug will be given to patients with different types of cancer to see if it shrinks their tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I will use effective birth control during and for 6 months after the study.I have recovered from recent surgery, radiation, or chemotherapy.My cancer can be measured by scans and has at least one visible tumor.My cancer is one of the specified types: triple negative breast, colon, rectum, liver, bone, ovarian, or stomach.I haven't received any cellular therapy in the last 12 weeks.I or someone I live with has a significant immune system problem.I am not currently on treatment for any serious infections.I haven't had experimental drugs or immunotherapy in the last 3 weeks.My condition has not improved with standard treatments, or I cannot tolerate them.I can take care of myself and am up and about more than half of my waking hours.I have or had an autoimmune disease, with some exceptions.My kidney and liver are working well.Women who could become pregnant must have a negative pregnancy test.My cancer has spread to my brain.I am currently taking or have recently taken steroids or other immune-suppressing drugs.I have had another type of cancer before.I haven't had chemotherapy in the last 3 weeks.I am 18 years old or older.I do not have HIV, hepatitis B or C, or any severe illness that could affect my study participation.My blood counts are within normal ranges.
- Group 1: Monotherapy Dose-Escalation Cohorts
- Group 2: Combination Therapy Cohorts
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is CRX100 suspension a viable infusion alternative for patients?
"CRX100 suspension for infusion's safety is estimated to be a rating of 1, due to the fact that this Phase 1 trial has limited evidence backing its efficacy and security."
Is the research team currently recruiting participants for this experiment?
"According to clinicaltrials.gov, this research attempt is actively seeking out participants. It was initially advertised on the 8th of January 2021 and has been amended as recently as 26 July 2022."
What is the participant count for this clinical research?
"Affirmative. According to the information posted on clinicaltrials.gov, this clinical trial is presently enrolling patients. The study was initially published on August 1st 2021 and last modified July 26th 2022; it seeks 24 subjects from 3 distinct medical facilities."
Share this study with friends
Copy Link
Messenger